Abstracts tagged "bone disease and treatment"

Abstract Number: 1939 • 2017 ACR/ARHP Annual Meeting
Dipyridamole, an Ent-1 Adenosine Transporter Inhibitor, Reverts De Osteoclastic Phenotype Induced By Tenofovir
Francisco Miguel Conesa-Buendia¹, Patricia Llamas², Tuere Wilder³, Patricia Atencio⁴, Alfonso Cabello⁵, Miguel Gorgolas⁴, Bruce Cronstein⁶, Raquel Largo⁷, Gabriel Herrero-Beaumont⁷ and Aranzazu Mediero⁸, ¹Bone and Joint Research Unit, IIS-Fundacion Jimenez Diaz- UAM, Madrid, Spain, ²Bone and Joint Research Unit, IIS-Fundacion Jimenez Díaz-UAM, Madrid, Spain, ³Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁴Internal Medicine Department, IIS-Fundacion Jimenez Diaz-UAM, Madrid, Spain, ⁵Internal MEdicine Department, IIS-Fundacion Jimenez Diaz-UAM, Madrid, Spain, ⁶Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY, ⁷Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain, ⁸Bone and Joint Research Unit, Fundación Jiménez Díaz-UAM, Madrid, Spain
Background/Purpose: Adenosine, generated from the catabolism of adenine nucleotides, modulates cell function by interacting with specific cell-surface receptors (A1R, A2AR, A2BR, A3R). Inhibition of osteoclast…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].